The Shilin District Court yesterday found OBI Pharma chairman Michael Chang (張念慈) and four other company executives not guilty of insider trading.
The acquittal was based on a lack of clear evidence that Chang, general manager Amy Huang (黃秀美), vice president Hsu Yo-gung (許友恭), research and development director Yu Cheng-te (游丞德) and administration division manager Liao Tsung-chih (廖宗智) committed insider trading, the court said in a statement.
It was the first ruling in the case related to the company’s development of the OBI-822 breast cancer drug and can still be appealed.
Chang was not present for the verdict and was represented by his lawyer, who said: “We always had confidence in the case and so the acquittal was the expected result.”
Prosecutors said that they would examine the ruling to decide whether to file for an appeal.
Insider trading charges were filed against the five in January 2017 under provisions of the Securities and Exchange Act (證券交易法).
Prosecutors had alleged that the executives in an August 2015 meeting learned that a double-blind clinical trial for OBI-822 had produced unsatisfactory results and from September 2015 to January 2016 sold their shares in the firm.
By selling the shares before the trial’s results were officially announced in February 2016, Chang avoided financial losses of NT$24.2 million (US$776,886 at the current exchange rate) and the others each avoided losses of more than NT$10 million, the prosecutors had said.
Although the five had learned about aspects of the trial’s results, at the time they did not know which set of patients was receiving the treatment and which was receiving a placebo, the ruling said, adding that there are always uncertainties associated with drug trials.
An investigation failed to provide clear evidence of insider trading, which Article 157-1 of the act defines as using “information that will have a material impact on the price of securities,” it said.
In December last year, the court acquitted former Academia Sinica president Wong Chi-huey (翁啟惠) in a related case of insider trading, as he was found to have acted on advice by his stock broker to sell part of his stake in the firm when prices were rising in February 2016.
Taipei-based OBI Pharma was founded by Chang and Wong in April 2002 as a wholly owned subsidiary of US-based Optimer Pharmaceuticals Inc.
Wong was reportedly the main consultant for the company in the development of OBI-822 and other biotechnology products.
Prosecutors had said that Wong in 2012 received 3 million OBI Pharma shares from Chang that were priced at NT$31 each when the firm was listed on the emerging stock market.
In 2013, the company’s stock was listed on the over-the-counter market at NT$310 per share.
The manufacture of the remaining 28 M1A2T Abrams tanks Taiwan purchased from the US has recently been completed, and they are expected to be delivered within the next one to two months, a source said yesterday. The Ministry of National Defense is arranging cargo ships to transport the tanks to Taiwan as soon as possible, said the source, who is familiar with the matter. The estimated arrival time ranges from late this month to early next month, the source said. The 28 Abrams tanks make up the third and final batch of a total of 108 tanks, valued at about NT$40.5 billion
Two Taiwanese prosecutors were questioned by Chinese security personnel at their hotel during a trip to China’s Henan Province this month, the Mainland Affairs Council (MAC) said yesterday. The officers had personal information on the prosecutors, including “when they were assigned to their posts, their work locations and job titles,” MAC Deputy Minister and spokesman Liang Wen-chieh (梁文傑) said. On top of asking about their agencies and positions, the officers also questioned the prosecutors about the Cross-Strait Joint Crime-Fighting and Judicial Mutual Assistance Agreement, a pact that serves as the framework for Taiwan-China cooperation on combating crime and providing judicial assistance, Liang
A group from the Taiwanese Designers in Australia association yesterday represented Taiwan at the Midsumma Pride March in Melbourne. The march, held in the St. Kilda suburb, is the city’s largest LGBTQIA+ parade and the flagship event of the annual Midsumma Festival. It attracted more than 45,000 spectators who supported the 400 groups and 10,000 marchers that participated this year, the association said. Taiwanese Designers said they organized a team to march for Taiwan this year, joining politicians, government agencies, professionals and community organizations in showing support for LGBTQIA+ people and diverse communities. As the first country in Asia to legalize same-sex
MOTIVES QUESTIONED The PLA considers Xi’s policies toward Taiwan to be driven by personal considerations rather than military assessment, the Epoch Times reports Chinese President Xi Jinping’s (習近平) latest purge of the Chinese People’s Liberation Army (PLA) leadership might have been prompted by the military’s opposition to plans of invading Taiwan, the Epoch Times said. The Chinese military opposes waging war against Taiwan by a large consensus, putting it at odds with Xi’s vision, the Falun Gong-affiliated daily said in a report on Thursday, citing anonymous sources with insight into the PLA’s inner workings. The opposition is not the opinion of a few generals, but a widely shared view among the PLA cadre, the Epoch Times cited them as saying. “Chinese forces know full well that
RSS